AAA603-NeoB-Breast

A Phase I/II open label multi-centre trial of 177Lu Lu-Neo-B in combination with capecitabine in adult patients with gastrin releasing peptide receptor positive oestrogen receptor positive human epidermal growth receptor-2 negative metastatic breast cancer after progression on previous endocrine therapy in combination with CDK 4/6 inhibitor

Enquire

Trial overview

Clinical Area

Theranostics

Disease / Condition

Breast Cancer

Study Phase

I/ll

Trial Identifiers

NCT06247995

https://clinicaltrials.gov/study/NCT06247995

GenesisCare Location(s)

Malvern (Cabrini Hospital)

Cabrini Hospital Malvern, Level B4, Gandel Wing, 183 Wattletree Road, Malvern, VIC, 3144, Australia

(03) 9597 6900

cabrinireception@genesiscare.com

Find out more Get directions

Principal Investigator(s)

Nuclear Medicine Physician

A/Prof Dinesh Sivaratnam

MBBS FRACP FAANMS, B.Med.Sci.

View Profile

Thank you for submitting.

We will be in touch within 24 hours

Form submission error

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.

First name *

Last name *

Email *

Phone *

+61

Postalcode *

State/territory *

What is the reason for enquiry?

How would you prefer to be contacted? *

Phone Email

By clicking “submit” below, you acknowledge we will use the information you are providing to contact you about your referral request. Refer to our Private Policy for more information about how we handle personal information.

Disclaimer:

This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.

Disclaimer: